Efficacy and safety of montelukast for pediatric obstructive sleep apnea syndrome

A protocol for systematic review and meta-analysis

Jun-Li Bao, PhD candidate, Xinyuan-Gao, PhD candidate, Yu-Bo Han, PhD, Ke Zhang, MD, Li Liu, PhD

Abstract

Background: Pediatric obstructive sleep apnea syndrome (OSAS) is significant public concern. Clinical practice indicates that montelukast has certain therapeutic advantages, while there is a lack of evidence-based medicine support. The aim of this study is to synthesize related data to explore efficacy and safety of montelukast for pediatric OSAS.

Methods: Data in Pubmed, EMBASE, CENTRAL, CBM, CNKI, WanFang, VIP databases were comprehensively searched. All the randomized controlled trials (RCTs) in OSAS children were identified, in which the effects of montelukast on a range of outcomes were compared. The search had a deadline of January 1, 2020. Two investigators independently conducted data extraction and assessed the literature quality of the included studies. The Revman5.3 software was used for meta-analysis of the included literature.

Results: The efficacy and safety of montelukast in the treatment of pediatric OSAS were evaluated in terms of apnea hypopnea index (AHI), the Pittsburgh Sleep Quality Index, the Epworth Sleep Scale (ESS), neck circumference, important index in Polysomnography: sleep efficiency, desaturation index, total sleep time.

Conclusions: This study provides reliable evidence-based support for the clinical application of montelukast in the treatment of pediatric OSAS.

PROSPERO registration number: CRD42020146940.

Abbreviations: AHI = apnea hypopnea index, CI = confidence interval, ESS = Epworth Sleep Scale, MD = mean differences, OSAS = Obstructive sleep apnea syndrome, PRISMA-P = preferred reporting items for systematic reviews and meta-analysis protocols, PSG = polysomnography, RCTs = randomized controlled trials, RR = risk ratios.

Keywords: meta-analysis, montelukast, pediatric obstructive sleep apnea syndrome

1. Introduction

Obstructive sleep apnea syndrome (OSAS) in children refers to a series of clinical syndromes caused by partial collapse or complete obstruction of upper airway during sleep, which disturbs normal ventilation and sleep structure during sleep. OSAS is characterized by snoring, mouth opening, restless sleep, enuresis, hyperhidrosis and inattention. In severe cases, OSAS can also lead to growth retardation, cognitive dysfunction, adenoid facial features and cardiovascular diseases. Adenoid hypertrophy or tonsillar hypertrophy is the main cause of OSAS in children. Surgical removal of adenoids and/or tonsils is the first choice for the treatment of childhood OSAS without contraindications. However, there are still a considerable number of OSAS children with adenoidectomy and/or tonsillectomy sleep apnea can not be completely improved. These has instigated exploration of nonsurgical therapeutic alternatives.

Previous studies demonstrated the abundant expressions of leukotrienes and their receptors in adenotonsillar tissues, which lead to the therapeutic use of leukotriene receptor antagonist such as montelukast in children who have mild OSAS. At present, several studies reported the significant benefits of montelukast in alleviating OSAS severity. However, it is not all children who responded to the treatment, restricting of the promotion of this method to a certain extent. Therefore, this study aimed to systematically assess the efficacy and safety of montelukast in the treatment of OSAS and provide a reliable reference for the clinical application of montelukast in the treatment of OSAS.

2. Methods

2.1. Protocol register

This protocol of systematic review and meta-analysis has been drafted under the guidance of the preferred reporting items for...
systematic reviews and meta-analysis protocols (PRISMA-P).[13] Moreover, it has been registered on the PROSPERO (registration number: CRD42020146940).

2.2. Ethics
Since this is a protocol with no patient recruitment and personal information collection, approval by the ethics committee is not required.

2.3. Eligibility criteria
2.3.1. Types of studies. We will collect all available randomized controlled trials (RCTs) on montelukast in the treatment of OSAS, regardless of publication status, and region, but language will be restricted to Chinese and English.

2.3.2. Patients. The patients (1–14 years old) were definitively diagnosed with OSAS in accordance with the polysomnography (PSG) with no limitation of nationality, race, sex, course of disease, etc.

2.3.3. Intervention. Patients in the treatment group received oral montelukast, while patients in the control group received placebo. There were no restrictions on the dose, frequency, and treatment course of montelukast.

2.3.4. Outcome indicators.
1. Primary outcome: Apnea hypopnea index (AHI) an index that indicate the severity of sleep apnea. It is presented by a count of the number of apneas and hypopneas per hour of sleep.[14]
2. Secondary outcomes: the Pittsburgh Sleep Quality Index,[15] the Epworth Sleep Scale (ESS),[16] neck circumference,[17] important index in Polysomnography: sleep efficiency, desaturation index, total sleep time.[18]

2.4. Exclusion criteria
1. Animal experiments, reviews, case reports, and repetitive publications or search outcomes.
2. The published papers were abstracts or the data were incomplete and the papers with complete data were not available after contacting the author.
3. Papers containing less than 10 cases;
4. Papers assessed as high risk of bias by randomization or concealed distribution.[19]
5. Papers with no relevant outcome indicators.

2.5. Information sources
The search will use a sensitive subject and topic-based strategy from inception to January 1, 2020. Databases searched will be PubMed, EMBASE, the Cochrane Central Register of Controlled Trials (CENTRAL), Chinese Biomedical Literature Database (CBM), China National Knowledge Infrastructure (CNKI), Wanfang Database and China Science and Technology Journal Database (VIP).

2.6. Search strategy
Take “montelukast (meng lu si te)”, “obstructive sleep apnea syndrome (zu sai xing shui mian hu xi zan ting zong he zheng)”, “snoring (da han)” as the Chinese search terms and search in Chinese databases, including CNKI, Wanfang, VIP. Take “montelukast”, “montelukast sodium”, “obstructive sleep apnea syndrome”, “Obstructive Sleep Apneas”, “Obstructive Sleep Apnea” as the English terms and search terms and search in English databases, including PubMed, EMBASE, CENTRAL, CBM were searched manually. Taking PubMed as an example, the retrieval strategy is shown in Table 1.

2.7. Data filtering and extraction
Referring to the method of research selection in version 5.0 of the Cochrane Collaboration Network System Evaluator Manual, according to the preferred reporting items for systematic reviews and meta-analysis (PRISMA) flow chart, 2 authors used the EndNote V.X9 document management software to independently screen and check the literature according to the above inclusion and exclusion criteria, and check each other. A third reviewer reviewed the extracted data and stored the original data in a secure computer to avoid additional changes. At the same time, Excel 2016 was used to extract relevant information, including: The variables, namely, article title, author(s), journal title, year of publication, sample size, sex, age, interventions, the duration of treatment, and outcome. The process of literature filtering is shown in Figure 1.

2.8. Literature quality assessment
The quality of all included studies was assessed by 2 authors. The AMSTAR measurement tool was adopted, consisting of 16 problems.[20]
1. Did the research questions and inclusion criteria for the review include the components of PICO?
2. Did the report of the review contain an explicit statement that the review methods were established prior to the conduct of

| Table 1 |
| --- |
| **Search strategy for the PubMed database.** |
| #1 montelukast |
| #2 montelukast sodium |
| #3 Singulair |
| #4 MK 0476 |
| #5 Sodium 1-((1-(3-(2-(7-chloro-2-quinolinyl)ethenyl)phenyl)-3-(2-hydroxy-1-methylethyl)phenyl)propyl)thio)methyl)cyclopropylacetate) |
| #6 Leukotriene Antagonists |
| #7 #1 OR #2 OR #3 OR #4 OR#5 OR #6 |
| #8 obstructive sleep apnea syndrome |
| #9 Apneas, Obstructive Sleep OR Obstructive Sleep Apneas |
| #10 Sleep Apneas, Obstructive |
| #11 Obstructive Sleep Apnea |
| #12 OSAHs |
| #13 Syndrome, Sleep Apnea, Obstructive |
| #14 Sleep Apnea Syndrome, Obstructive |
| #15 Apnea, Obstructive Sleep |
| #16 Sleep Apnea Hypopnea Syndrome |
| #17 Syndrome, Obstructive Sleep Apnea |
| #18 Upper Airway Resistance Sleep Apnea Syndrome |
| #19 Syndrome, Upper Airway Resistance, Sleep Apnea |
| #20 OR #6 OR #9 OR #10 OR #11 OR #12 OR #13 OR #14 OR #15 OR #16 OR #17 OR #18 OR #19 |
| #21 OR #7 AND #20 |
10. Did the review authors account for RoB in primary studies when interpreting/discussing the results of the review?
14. Did the review authors provide a satisfactory explanation for, and discussion of, any heterogeneity observed in the results of the review?
15. If they performed quantitative synthesis did the review authors carry out an adequate investigation of publication bias (small study bias) and discuss its likely impact on the results of the review?
16. Did the review authors report any potential sources of conflict of interest, including any funding they received for conducting the review?

Discrepancy was resolved through the discussion between the 2 reviewers. Judgments were independently made by 2 investigators; disagreements were remedied after the discussion with a third investigator.

2.9. Statistical analysis
2.9.1. Data analysis and processing. A meta-analysis was conducted using RevMan 5.3 only when enough and suitable data were harvested. In terms of dichotomous variable, the results
were calculated as risk ratios (RR). For continuous variable, mean differences (MD) were adopted. Both of the mentioned elements corresponding to 95% confidence interval (CI) were calculated. Heterogeneity was ascertained using the I². I² < 50% revealed that the studies exhibited homogeneity, so fixed effects model was used; otherwise, the random effects model was used. In the presence of heterogeneity, sensitivity analyses would be conducted to investigate heterogeneity sources.

2.9.2. Dealing with missing data. If there are missing data in the article, contact the author via email for additional information. If the author cannot be contacted, or the author has lost relevant data, descriptive analysis will be conducted instead of meta-analysis.

2.9.3. Sensitivity analysis. In order to test the stability of meta-analysis results of indicators, a one-by-one elimination method will be adopted for sensitivity analysis.

2.9.4. Assessment of reporting biases. Publication bias was assessed by funnel plot and Egger test. Egger test was performed for no less than 10 studies, whereas the trim-and-fill analysis was conducted in the presence of publication bias.

2.9.5. Evidence quality evaluation. The AMSTAR measurement tool will be used to assess the quality of evidence. The quality of evidence will be rated as high, moderate, low, and very low.

3. Discussion
OSAS is a common and highly prevalent disorder in the pediatric age range.[21] OSAS imposes a vast array of morbidities including neurocognitive, behavioral, cardiovascular, and metabolic.[22] Pediatric OSAS is usually treated by adenotonsillectomy. However, a substantial proportion of children with OSAS undergoing adenotonsillectomy may develop postoperative complications and have persistent disease after surgery.[23] In recent years, nonsurgical therapeutic alternatives has been explored actively.[24] Some studies suggested that montelukast could be effective.[25] This study aimed to systematically assess the efficacy and safety of montelukast in the treatment of pediatric OSAS and provide a reliable reference for the clinical application of montelukast in the treatment of pediatric OSAS.

However, this systematic review had some limitations: there were differences in the doses of montelukast used in the included studies and the condition of the patients disease. There may be some clinical heterogeneity. The course of disease was also different, which may have affected the results to some extent. Constrained by language ability, we only searched English and Chinese literature and may ignore studies or reports in other languages.

Author contributions
Conceptualization: Junli Bao.
Data curation: Xinyuan Gao.
Funding acquisition: Li Liu.
Investigation: Yubo Han.
Methodology: Ke Zhang.
Project administration: Junli Bao.
Software: Junli Bao, Xinyuan Gao.
Supervision: Yubo Han.
Validation: Xinyuan Gao.
Writing – original draft: Junli Bao, Xinyuan Gao.
Writing – review & editing: Junli Bao, Li Liu.

References
[1] Chandrakantan A, Musso MF, Floyd T, et al. Pediatric obstructive sleep apnea: preoperative and neurocognitive considerations for perioperative management. Paediatr Anaesth 2020;31:110420.
[2] Lee T, Wolfo维奇 S, Kettler E, et al. Incidence of cure and residual obstructive sleep apnea in obese children after tonsillectomy and adenoidectomy stratified by age group. Int J Pediatr Otorhinolaryngol 2020;28:110394.
[3] Bhan XM, Han GH, Liu Y, et al. Research progress on the relationship between obstructive sleep apnea hypopnea syndrome and multiple system diseases in children. Chin Arch Otolaryngol Head Neck Surg 2019;26:325–8. (In Chinese).
[4] Esteller E, Villatoro JC, Aguero A, et al. Obstructive sleep apnea syndrome and growth failure. Int J Pediatr Otorhinolaryngol 2018;108:214–8.
[5] Tian JH, Zhao J, Wang GX, et al. Clinical study on the correlation between sleep snoring and intelligence level in children aged 4-6 years. Chin J Otorhinolaryngol Head Neck Surg 2018;25:380–3. (In Chinese).
[6] Arv A, Kemaloglu YK, Yilmaz M, et al. Craniofacial deviations in the children with nasal obstruction. J Craniofac Surg 2017;28:625–8.
[7] Li D, Li XH. Relationship between obstructive sleep apnea hypopnea syndrome and cardiovascular diseases in children. J Cardiovascular Pulmonary Dis 2017;36:1042–5. (In Chinese).
[8] Wu ZK, Zhu XH. Error study of adenotonsillectomy in the treatment of obstructive sleep apnea syndrome in children. J Otolaryngol Ophthalmolol Shandong Unv 2019;33:148–52. (In Chinese).
[9] Boudewyns A, Abel F, Alexopoulos E, et al. Adenotonsillolithy to treat obstructive sleep apnea: is it enough? Pediatr Pulmonol 2017;52:699–709.
[10] Sunkonkit K, Sriripanyakawan S, Veeravikrom M, et al. Urinary cysteinyl leukotriene E4 level and therapeutic response to montelukast in children with mild obstructive sleep apnea. Asian Pac J Allergy 2017;35:233–8.
[11] Limung BJ, Ryan M, Mack D, et al. Montelukast and nasal corticosteroids to treat pediatric obstructive sleep apnea: a systematic review and meta-analysis. Otolaryngol Head Neck Surg 2019;160:594–602.
[12] Kheirandish-Gozal L, Bandila HP, Gozal D. Montelukast for children with obstructive sleep apnea: results of a double-blind, randomized, placebo-controlled trial. Ann Am Thorac Soc 2016;13:1736–41.
[13] Booth A, Mitchell AS, Mott A, et al. An assessment of the extent to which the contents of PROSPERO records meet the systematic review protocol reporting items in PRISMA-P. E1000 Rev 2020;27:773.
[14] Samirad S, Khoshbari A, Rezaeeitalab F, et al. Will obstructive sleep apnea and apnea/hypopnea index be corrected following alveolar cleft reconstruction? World J Plast Surg 2020;9:146–52.
[15] Chehri A, Brand S, Goldaste N. Psychometric properties of the persian pittsburgh sleep quality index for adolescents. Int J Environ Res Public Health 2020;17:E7095.
[16] Chen X, Zhang R, Wang HH, et al. The assessed value of Epworth sleep scale and arousals index in severe OSAHS patients. J Clin Otorhinolaryngol 2017;31:167–9.
[17] Castorena-Maldonado A, Espinosa-Morett L, Bosque FAD, et al. Diagnostic value of the morphometric model and adjusted neck circumference in adults with obstructive sleep apnea syndrome. Rev Invest Clin 2015;67:258–65.
[18] Chousangunotnorn K, Blongmakapat T, Apirakkittikul N, et al. Computed tomography characterization and comparison with polysomnography for obstructive sleep apnea evaluation. J Oral Maxillofac Surg 2017;76:854–72.
[19] Zhao JG, Zeng XT, Wang J, et al. Association between calcium or Vitamin D supplementation and fracture incidence in community-dwelling older adults: a systematic review and meta-analysis. JAMA 2017;318:2466–82.
[20] Shea BJ, Reeves BC, Wells G, et al. AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both. BMJ 2017;358:j4008.
[21] Chandrakantan A, Adler AC. Pediatric obstructive sleep apnea and neurocognition. Anesthesiol Clin 2020;38:693–707.
[22] Chandrakantan A, Musso MF, Floyd T, et al. Pediatric obstructive sleep apnea: preoperative and neurocognitive considerations for perioperative management. Paediatr Anaesth 2020;30:529–36.

[23] Isaiah A, Spanier AJ, Grattan LM, et al. Predictors of behavioral changes after adenotonsillectomy in pediatric obstructive sleep apnea: a secondary analysis of a randomized clinical trial. JAMA Otolaryngol Head Neck Surg 2020;146:1–9.

[24] Chorney SR, Zur KB. Adenoidectomy without tonsillectomy for pediatric obstructive sleep apnea. Otolaryngol Head Neck Surg 2020;22:194599820955172.

[25] Smith DF, Sarber KM, Spiceland CP, et al. Effects of medical therapy on mild obstructive sleep apnea in adult patients. J Clin Sleep Med 2019;15:979–83.